News – Sound Bioventures

All Fund articles Fund PR Portfolio articles Portfolio PR

VarmX announces publication of sensitive coagulation assays to assess restoration of coagulation using VMX-C001 in the presence of Factor Xa inhibitors

2026.02.252026.02.25 / Key highlights The collaborative study with Coagulation Profile BV, Maastricht University and Leiden University Medical Center has been accepted for publication in Research and Practice in Thromb ...

Boost Pharma

Hans Schambye Appointed as Chief Executive Officer of BOOST Pharma

2026.02.102026.02.10 / Advancing development of lead candidate BT-101, a potential disease-modifying treatment for Brittle Bone Disease Preparing for Phase III development following promising data showing reduced fract ...

Strong clinical data for Breye Therapeutics’ lead oral asset danegaptide presented at Angiogenesis, Exudation and Degeneration 2026 symposium

2026.02.092026.02.09 / Prof. Carl D. Regillo, MD, presented clinical data from the Phase 1b trial evaluating Breye Therapeutics’ lead candidate, danegaptide, in 24 patients with non-proliferative diabetic retinopathy (NPD ...

Teitur Trophics Initiates Dosing of First Parkinson’s Disease Patient in Clinical Trial at CHDR, Leiden

2026.01.262026.01.26 / Teitur Trophics today announce the dosing of the first two patients with Parkinson’s disease in the Phase I trial for TT-P34, conducted at the Centre for Human Drug Research (CHDR) in Leiden, the Net ...

Teitur Trophics Initiates First Clinical Trial in Patients with Parkinson’s Disease

2026.01.262026.01.26 / Teitur Trophics is pleased to announce the initiation of its first clinical trial in patients with Parkinson’s disease. The study marks an important milestone in the company’s ongoing Phase I clinica ...

Sound Bioventures - Team 2025

Sound Bioventures 2025 Achievements & Highlights

2025.12.172025.12.17 / Our mission is driving innovation in life sciences by backing transformative companies addressing high unmet medical needs. We have added two new Principals to our investment team During the ye ...

AnaCardio Reports Strong Phase 2a Topline Results for AC01 in patients with heart failure and reduced ejection fraction (HFrEF); Paving the Way for Rapid Advancement to Phase 2b

2025.12.102025.12.10 / December 10, 2025, Stockholm, Sweden – AnaCardio, a clinical-stage biopharmaceutical company developing novel contractile agents for heart failure, today announces strong topline results from the Pha ...

BOOST Pharma Pressrelease

BOOST Pharma Adds Sound Bioventures to Investor Syndicate to Advance Stem Cell Therapy for Osteogenesis Imperfecta

2025.11.032026.02.10 / Copenhagen, Denmark – November 3, 2025 – BOOST Pharma ApS, a clinical-stage biopharmaceutical company focused on developing novel cell therapies for rare skeletal pediatric diseases, today announced ...

Aboleris Pharma Appoints Seasoned Life-Sciences Executive Philippe Alen as Chief Business Officer

2025.10.302025.12.02 / Gosselies, Belgium and Nantes, France, October 30, 2025 /PRNewswire/ -- AbolerIS Pharma (“AbolerIS”), a clinical-stage biopharmaceutical company committed to improving the lives of people suffering f ...

Theolytics to Present Ongoing Phase I/IIa OCTOPOD-IV Trial of THEO-260 in Ovarian Cancer at ESMO 2025

2025.10.132025.12.02 / THEO-260 is an oncolytic immunotherapy developed for effective targeting of cancer cells and cancer-associated fibroblasts, whilst inducing immune activation in stromal rich tumours UK clinical t ...

Theolytics Appoints Experienced Medical Oncologist Matilde Saggese, MD, as Chief Medical Officer

2025.10.072025.12.02 / Dr Saggese will lead the expansion of the company's clinical trials with lead oncolytic immunotherapy THEO-260 THEO-260, is currently being investigated in patients with platinum-resistant ovaria ...

VarmX receives Phase 1 waiver from Japanese regulator PMDA

2025.09.252025.09.25 / for lead asset VMX-C001 Japanese regulator, the PMDA, waived the requirement for a Phase 1 trial in Japanese subjects for lead asset VMX-C001, enabling it to go straight to Phase 3 development ...